Table of Contents 1. Report scope & Methodology 1.1 Scope of the Report 1.2 Research Methodology 1.3 Executive Summary 2. Strategic Recommendations 2.1 APAC region to witness augmented growth in the forecast period. 2.2 Invest in Research and Development activities 3. Global Human Microbiome Market: Product Outlook 4. Global Human Microbiome Market: Sizing and Forecast 4.1 Market Size, By Value, Year 2014-2024 5. Global Human Microbiome Market Segmentation By Product 5.1 Competitive Scenario of Global Human Microbiome Market – By Product 5.2 Probiotics – Market Size and Forecast (2019-2024) 5.3 Prebiotics - Market Size and Forecast (2019-2024) 5.4 Medical Foods - Market Size and Forecast (2019-2024) 5.5 Others - Market Size and Forecast (2019-2024) 6. Global Human Microbiome Market Segmentation By Disease 6.1 Competitive Scenario of Global Human Microbiome – By Disease 6.2 Obesity – Market Size and Forecast (2019-2024) 6.3 Diabetes Type II - Market Size and Forecast (2019-2024) 6.4 Autoimmune Disorder – Market Size and Forecast (2019-2024) 6.5 Cancer – Market Size and Forecast (2019-2024) 6.6 Gastrointestinal Disorder – Market Size and Forecast (2019-2024) 6.7 Others – Market Size and Forecast (2019-2024) 7. Global Human Microbiome Market Segmentation By Application 7.1 Competitive Scenario of Global Human Microbiome: By Application 7.2 Therapeutics – Market Size and Forecast (2019-2024) 7.3 Diagnostics - Market Size and Forecast (2019-2024) 8. Global Human Microbiome Market: Regional Analysis 8.1 Competitive Scenario of Global Human Microbiome: By Region 9. North America Human Microbiome Market: Segmentation By Products, Disease, Application (2019-2024) 9.1 North America Human Microbiome Market: Size and Forecast (2019-2024) 9.2 Market Segmentation By Products (Probiotics, Prebiotics, Medical Food & Other) 9.3 Market Segmentation By Disease (Obesity, Diabetes Type-II, Autoimmune Disorder, Cancer, Gastrointestinal Disorder & Others) 9.4 Market Segmentation By Application (Therapeutics & Diagnostics) 9.5 North America Human Microbiome Market: Country Analysis 9.6 Market Opportunity Chart of North America Human Microbiome Market - By Country, By Value (Year-2024) 9.7 Competitive Scenario of North America Human Microbiome: By Country 9.8 United States Human Microbiome Market: Size and Forecast (2019-2024) 9.9 United States Human Microbiome Market Segmentation By Product, Disease, Application 9.10 Canada Human Microbiome Market: Size and Forecast (2019-2024) 9.11 Canada Human Microbiome Market Segmentation By Product, Disease, Application 9.12 Mexico Human Microbiome Market: Size and Forecast (2019-2024) 9.13 Mexico Human Microbiome Market Segmentation By Products, Disease, Application 10. Europe Human Microbiome Market: Segmentation By Product, Disease, Application (2019-2024) 10.1 Europe Human Microbiome Market: Size and Forecast (2019-2024) 10.2 Market Segmentation By Products (Probiotics, Prebiotics, Medical Food & Other) 10.3 Market Segmentation By Disease (Obesity, Diabetes Type-II, Autoimmune Disorder, Cancer, Gastrointestinal Disorder & Others) 10.4 Market Segmentation By Application (Therapeutics & Diagnostics) 10.5 Europe Human Microbiome Market: Country Analysis 10.6 Market Opportunity Chart of Europe Human Microbiome Market - By Country, By Value (Year-2024) 10.7 Competitive Scenario of Europe Human Microbiome: By Country 10.8 United Kingdom Human Microbiome Market: Size and Forecast (2019-2024) 10.9 United Kingdom Human Microbiome Market Segmentation By Product, Disease, Application 10.10 Germany Human Microbiome Market: Size and Forecast (2019-2024) 10.11 Germany Human Microbiome Market Segmentation By Product, Disease, Application 10.12 France Human Microbiome Market: Size and Forecast (2019-2024) 10.13 France Human Microbiome Market Segmentation By Products, Disease, Application 10.14 Rest of the Europe Human Microbiome Market: Size and Forecast (2019-2024) 10.15 Rest of the Europe Human Microbiome Market Segmentation By Products, Disease, Application 11. Asia Pacific Human Microbiome Market: Segmentation By Products, Disease, Application (2019-2024) 11.1 Asia Pacific Human Microbiome Market: Size and Forecast (2019-2024) 11.2 Market Segmentation By Products (Probiotics, Prebiotics, Medical Food & Other) 11.3 Market Segmentation By Disease (Obesity, Diabetes Type-II, Autoimmune Disorder, Cancer, Gastrointestinal Disorder & Others) 11.4 Market Segmentation By Application (Therapeutics & Diagnostics) 11.5 Asia Pacific Human Microbiome Market: Country Analysis 11.6 Market Opportunity Chart of Asia Pacific Human Microbiome Market - By Country, By Value (Year-2024) 11.7 Competitive Scenario of Asia Pacific Human Microbiome: By Country 11.8 China Human Microbiome Market: Size and Forecast (2019-2024) 11.9 China Human Microbiome Market Segmentation By Product, Disease, Application 11.10 India Human Microbiome Market: Size and Forecast (2019-2024) 11.11 India Human Microbiome Market Segmentation By Product, Disease, Application 11.12 Japan Human Microbiome Market: Size and Forecast (2019-2024) 11.13 Japan Human Microbiome Market Segmentation By Products, Disease, Application 11.14 South Korea Human Microbiome Market: Size and Forecast (2019-2024) 11.15 South Korea Human Microbiome Market Segmentation By Products, Disease, Application 11.16 Rest of the Asia Pacific Human Microbiome Market: Size and Forecast (2019-2024) 11.17 Rest of the Asia Pacific Human Microbiome Market Segmentation By Products, Disease, Application 12. Rest of the World Human Microbiome Market: Segmentation By Products, Disease, Application (2019-2024) 12.1 Rest of the World Human Microbiome Market: Size and Forecast (2019-2024) 12.2 Market Segmentation By Products (Probiotics, Prebiotics, Medical Food & Other) 12.3 Market Segmentation By Disease (Obesity, Diabetes Type-II, Autoimmune Disorder, Cancer, Gastrointestinal Disorder & Others) 12.4 Market Segmentation By Application (Therapeutics & Diagnostics) 13. Global Human Microbiome Market Dynamics 13.1 Global Human Microbiome Market Drivers 13.2 Global Human Microbiome Market Restraints 13.3 Global Human Microbiome Market Trends 14. Market Attractiveness and Strategic Analysis 14.1 Market Attractiveness 14.1.1 Market Attractiveness Chart of Global Human Microbiome Market - By Products (Year 2024) 14.1.2 Market Attractiveness Chart of Global Human Microbiome Market - By Disease (Year 2024) 14.1.3 Market Attractiveness Chart of Global Human Microbiome Market - By Application (Year-2024) 14.1.4 Market Attractiveness Chart of Global Human Microbiome Market - By Region, By Value, (Year-2024) 14.2 Strategic Analysis 14.2.1 Key Developments in Human Microbiome Market 14.2.3 Human Microbiome Pipeline Projects 15. Competitive Landscape 15.1 Microbiome Licensing Deals Between Big Pharma and Biotech 15.2 Market Share Analysis 15.3 SWOT Analysis 15.4 Porter’s Five Force Analysis 16. Company Profiles (Business Description, Financial Analysis, Business Strategy) 16.1 OptiBiotix Health Plc 16.2 Metabiomics 16.3 OSEL Inc. 16.4 PureTech Health 16.5 4D Pharma 16.6 Synlogic Inc. 16.7 BaseClear BV 16.8 Rebiotix Inc 16.9 Ritter Pharmaceuticals 16.10 Assembly Bioscience Inc.

List of Figures Figure 1: Global Human Microbiome Market Size, By Value, 2014-2024 (USD Million) Figure 2: Healthcare Expenditure (Share of GDP), By Selected Country, 2013-2017 (In %) Figure 3: Number of New Cases of Cancer, In 2018, By Region, (% of Total) Figure 4: Number of New Cases of Cancer, 2018, By Type, (% of Total) Figure 5: Global Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Millions) Figure 6: Global Prevalence of Diabetes Type II, 2014-2017 (In Millions) Figure 7: Prevalence of Diagnosed Autoimmune Diseases, In 2018, By Selected Countries, (% of Total) Figure 8: Prevalence of diagnosed gastrointestinal conditions, By Select Countries, 2017 (In %) Figure 9: Global Aged Population (Above 65), 2013-2017 (% of total) Figure 10: Global Aged Population(Above 65), By Country, 2017 (% of total) Figure 11: Number of microbiome modulators in active development, by year, 2012–17 Figure 12: Global Microbiome, No. of active drugs in market Figure 13: Obese Population, By Country, 2017 (In Millions) Figure 14: Inner Pie: Segmental Analysis By Product: Year 2018, Outer Pie: Segmental Analysis By Product: Year 2024 Figure 15: Global Human Microbiome Market- By Probiotic, By Value (USD Million), 2014-2024 Figure 16: Global Human Microbiome Market- By Prebiotic, By Value (USD Million), 2014-2024 Figure 17: Global Human Microbiome Market- By Medical Food, By Value (USD Million), 2014-2024 Figure 18: Global Human Microbiome Market- By Others, By Value (USD Million), 2014-2024 Figure 19: Inner Pie: Segmental Analysis By Disease: Year 2018, Outer Pie: Segmental Analysis By Disease: Year 2024 Figure 20: Global Human Microbiome Market- By Obesity, By Value (USD Million), 2014-2024 Figure 21: Inner Global Human Microbiome Market- By Diabetes Type II, By Value (USD Million), 2014-2024 Figure 22: Global Human Microbiome Market- By Autoimmune Disorder, By Value (USD Million), 2014-2024 Figure 23: Global Human Microbiome Market- By Cancer, By Value (USD Million), 2014-2024 Figure 24: Global Human Microbiome Market- By Gastrointestinal Disorder, By Value (USD Million), 2014-2024 Figure 25: Global Human Microbiome Market- By Others, By Value (USD Million), 2014-2024 Figure 26: Inner Pie: Segmental Analysis By Application: Year 2018, Outer Pie: Segmental Analysis By Application: Year 2024 Figure 27: Global Human Microbiome Market- By Therapeutic, By Value (USD Million), 2014-2024 Figure 28: Global Human Microbiome Market- By Diagnostics, By Value (USD Million), 2014-2024 Figure 29: Global Market Scenario, By Region (USD Million) Figure 30: Inner Pie: Segmental Analysis By Region: Year 2018, Outer Pie: Segmental Analysis By Region: Year 2024 Figure 31: North America Human Microbiome Market Size, By Value, 2014-2024 (USD Million) Figure 32: United States health care expenditure per capita,2013-2016(USD) Figure 33: Canada health care expenditure per capita,2013-2016(USD) Figure 34: North America Healthcare Cost Per Capita, 2017 (USD) Figure 35: North America population aged 65 and above, 2013-2017 (% of total) Figure 36: North America Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Millions) Figure 37: North America Prevalence of Diabetes Type II, 2014-2017 (In Millions) Figure 38: North America Human Microbiome Market- By Products, By Value (USD Million), 2014-2024 Figure 39: North America Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024 Figure 40: North America Human Microbiome- By Application, By Value (USD Million), 2014-2024 Figure 41: Market Opportunity Chart of North America Human Microbiome Market - By Country, By Value (Year-2024) Figure 42: Inner Pie: Segmental Analysis By Country: Year 2018, Outer Pie: Segmental Analysis By Country: Year 2024 Figure 43: United States Human Microbiome Market Size, By Value, 2014-2024 (USD Million) Figure 44: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD) Figure 45: U.S., Population ages 65 and above, 2013-2017 (% of total) Figure 46: U.S., Percentage of IBD patients that received select treatments as of 2017 (in %) Figure 47: Medical and Healthcare Research & Development Spending, 2013-2016 (In USD Million) Figure 48: United States Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Millions) Figure 49: United States Prevalence of Diabetes Type II, 2014-2017 (In Millions) Figure 50: United States Human Microbiome Market- By Products, By Value (USD Million), 2014-2024 Figure 51: United States Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024 Figure 52: United States Human Microbiome- By Application, By Value (USD Million), 2014-2024 Figure 53: Canada Human Microbiome Market Size, By Value, 2014-2024 (USD Million) Figure 54: Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %) Figure 55: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD) Figure 56: Canada, Population ages 65 and above, 2012-2017 (% of total) Figure 57: Canada Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands) Figure 58: Canada Prevalence of Diabetes Type II, 2014-2017 (In Millions) Figure 59: Prevalence of Diabetics in Canada, (% of Total Population) 2015 & 2045E Figure 60: Estimated Prevalence of Pre-Diabetics in Canada, (% of Total Population) 2015 & 2045E Figure 61: Overweight and Obese Population in Canada, 2015-2017 (% of total) Figure 62: Canada Human Microbiome Market- By Products, By Value (USD Million), 2014-2024 Figure 63: Canada Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024 Figure 64: Canada Human Microbiome- By Application, By Value (USD Million), 2014-2024 Figure 65: Mexico Human Microbiome Market Size, By Value, 2014-2024 (USD Million) Figure 66: Mexico Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands) Figure 67: Mexico Prevalence of Diabetes Type II, 2014-2017 (In Millions) Figure 68: Mexico Human Microbiome Market- By Products, By Value (USD Million), 2014-2024 Figure 69: Mexico Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024 Figure 70: Mexico Human Microbiome- By Application, By Value (USD Million), 2014-2024 Figure 71: Europe Human Microbiome Market Size, By Value, 2014-2024 (USD Million) Figure 72: European Country Population Aged 65 and Above, 2012-2017 (% of Total) Figure 73: European Union, Population ages 65 and above, 2013-2017 (% of total) Figure 74: Prevalence of Diabetes (Age 18+), 2017 & 2045E (In Million) Figure 75: Diabetes Prevalence (% of population ages 20 to 79), By Select Country, 2017 Figure 76: Europe Health Expenditure, By Select Country, 2016 (% of GDP) Figure 77: Europe Population ages 65 years and above (% of total population), 2013-17 Figure 78: Europe Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Millions) Figure 79: Europe Prevalence of Diabetes Type II, 2014-2017 (In Millions) Figure 80: Per Capita Health Expenditure, By Select Country, 2017 (USD) Figure 81: Europe Human Microbiome Market- By Products, By Value (USD Million), 2014-2024 Figure 82: Europe Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024 Figure 83: Europe Human Microbiome- By Application, By Value (USD Million), 2014-2024 Figure 84: Market Opportunity Chart of Human Microbiome Market - By Country, By Value (Year-2024) Figure 85: Inner Pie: Segmental Analysis By Country: Year 2018, Outer Pie: Segmental Analysis By Country: Year 2024 Figure 86: United Kingdom Human Microbiome Market Size, By Value, 2014-2024 (USD Million) Figure 87: U.K, Health Expenditure, (% of GDP), 2013-2017 (USD) Figure 88: U.K, Population Ages 65 and Above (% of total), 2012-2017 Figure 89: UK, Prevalence of Cancer, 2018, (% of Total) Figure 90: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person) Figure 91: U.K, Cause of Death, Percentage Change Between 2007-2017 Figure 92: United Kingdom Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands) Figure 93: United Kingdom Prevalence of Diabetes Type II, 2014-2017 (In Millions) Figure 94: United Kingdom Human Microbiome Market- By Products, By Value (USD Million), 2014-2024 Figure 95: United Kingdom Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024 Figure 96: United Kingdom Human Microbiome- By Application, By Value (USD Million), 2014-2024 Figure 97: Germany Human Microbiome Market Size, By Value, 2014-2024 (USD Million) Figure 98: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person) Figure 99: Germany, Population ages 65 and above, 2012-2017 (% total) Figure 100: Germany Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands) Figure 101: Germany Prevalence of Diabetes Type II, 2014-2017 (In Millions) Figure 102: Germany Human Microbiome Market- By Products, By Value (USD Million), 2014-2024 Figure 103: Germany Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024 Figure 104: Germany Human Microbiome- By Application, By Value (USD Million), 2014-2024 Figure 105: France Human Microbiome Market Size, By Value, 2014-2024 (USD Million) Figure 106: France, Health Expenditure, (% of GDP), 2012-2015 (USD) Figure 107: France, Population Ages 65 and Above (% of total), 2012-2017 Figure 108: France, Spending on Healthcare, 2015 & 2040$, (USD Per Person) Figure 109: France Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands) Figure 110: France Prevalence of Diabetes Type II, 2014-2017 (In Millions) Figure 111: France Human Microbiome Market- By Products, By Value (USD Million), 2014-2024 Figure 112: France Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024 Figure 113: France Human Microbiome- By Application, By Value (USD Million), 2014-2024 Figure 114: Rest of The Europe Human Microbiome Market Size, By Value, 2014-2024 (USD Million) Figure 115: Rest of The Europe Human Microbiome Market- By Products, By Value (USD Million), 2014-2024 Figure 116: Rest of The Europe Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024 Figure 117: Rest of The Europe Human Microbiome- By Application, By Value (USD Million), 2014-2024 Figure 118: APAC Human Microbiome Market Size, By Value, 2014-2024 (USD Million) Figure 119: Population ages 65 and above, APAC Region, By Select Countries, 2017 (% of total) Figure 120: Population ages 65 and above, APAC Region, By Select Countries, 2050 (% of total) Figure 121: Diabetes Prevalence (% of population ages 20 to 79), By Selected Country, 2017 Figure 122: Obesity Rate, By Selected Country, 2017 (In Percentage) Figure 123: Asia Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Millions) Figure 124: Asia Prevalence of Diabetes Type II, 2014-2017 (In Millions) Figure 125: Obesity Rate, By Select Country, 2017 (In Percentage) Figure 126: APAC Human Microbiome Market- By Products, By Value (USD Million), 2014-2024 Figure 127: APAC Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024 Figure 128: APAC Human Microbiome- By Application, By Value (USD Million), 2014-2024 Figure 129: Market Opportunity Chart of APAC Human Microbiome Market - By Country, By Value (Year-2024) Figure 130: Inner Pie: Segmental Analysis By Country: Year 2018, Outer Pie: Segmental Analysis By Country: Year 2024 Figure 131: China Human Microbiome Market Size, By Value, 2014-2024 (USD Million) Figure 132: China, Population Ages 65 and Above, 2012-2017 (% of total) Figure 133: China, Cancer Incidences ( in Million) Figure 134: China Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Millions) Figure 135: China Prevalence of Diabetes Type II, 2014-2017 (In Millions) Figure 136: China Human Microbiome Market- By Products, By Value (USD Million), 2014-2024 Figure 137: China Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024 Figure 138: China Human Microbiome- By Application, By Value (USD Million), 2014-2024 Figure 139: India Human Microbiome Market Size, By Value, 2014-2024 (USD Million) Figure 140: India, Population Ages 65 and Above, 2013-2017 Figure 141: India Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands) Figure 142: India Prevalence of Diabetes Type II, 2014-2017 (In Millions) Figure 143: India, Diseases Outlook & India, Medical Industry Outlook Figure 144: India Human Microbiome Market- By Products, By Value (USD Million), 2014-2024 Figure 145: India Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024 Figure 146: India Human Microbiome- By Application, By Value (USD Million), 2014-2024 Figure 147: Japan Human Microbiome Market Size, By Value, 2014-2024 (USD Million) Figure 148: Japan, GDP Growth Per Year, 2015-2019F (In %) Figure 149: Japan Healthcare Expenditure Outlook (%) Figure 150: Japan, Population ages 65 and above, 2012-2016 (% of total) Figure 151: Japan Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands) Figure 152: Japan Prevalence of Diabetes Type II, 2014-2017 (In Millions) Figure 153: Japan Human Microbiome Market- By Products, By Value (USD Million), 2014-2024 Figure 154: Japan Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024 Figure 155: Japan Human Microbiome- By Application, By Value (USD Million), 2014-2024 Figure 156: South Korea Human Microbiome Market Size, By Value, 2014-2024 (USD Million) Figure 157: South Korea Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands) Figure 158: South Korea Prevalence of Diabetes Type II, 2014-2017 (In Millions) Figure 159: South Korea Human Microbiome Market- By Products, By Value (USD Million), 2014-2024 Figure 160: South Korea Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024 Figure 161: South Korea Human Microbiome- By Application, By Value (USD Million), 2014-2024 Figure 162: Rest of the APAC Human Microbiome Market Size, By Value, 2014-2024 (USD Million) Figure 163: Rest of the APAC Human Microbiome Market- By Products, By Value (USD Million), 2014-2024 Figure 164: Rest of the APAC Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024 Figure 165: Rest of the APAC Human Microbiome- By Application, By Value (USD Million), 2014-2024 Figure 166: Rest of the World Human Microbiome Market Size, By Value, 2014-2024 (USD Million) Figure 167: Latin America and Caribbean, Population ages 65 and above (% of total) Figure 168: Middle East and North Africa, Population ages 65 and above (% of total) Figure 169: Cancer Prevalence in Latin America & Caribbean , (% of total), 2018 Figure 170: Population ages 65 and above, By Select Country, 2018 (% of total) Figure 171: Population ages 60 or above, By Select Country, 2050 (% of total) Figure 172: ROW Human Microbiome Market- By Products, By Value (USD Million), 2014-2024 Figure 173: ROW Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024 Figure 174: ROW Human Microbiome- By Application, By Value (USD Million), 2014-2024 Figure 175: Market Attractiveness Chart of Global Human Microbiome Market - By Products (Year-2024) Figure 176: Market Attractiveness Chart of Global Human Microbiome Market - By Disease (Year-2024) Figure 177: Market Attractiveness Chart of Global Human Microbiome Market - By Application (Year-2024) Figure 178: Market Attractiveness Chart of Global Human Microbiome Market - By Region, By Value, (Year-2024) Figure 179: OptiBiotix Health Plc Annual Revenue (USD Th.), Year 2015-2018 Figure 180: OptiBiotix Health Plc Net Profit/Loss (USD Th.), Year 2014-2018 Figure 181: PureTech Health Annual Revenue (USD Million), Year 2014-2018 Figure 182: PureTech Health Net Profit/Loss (USD Million), Year 2014-2018 Figure 183: 4D Pharma Investment in R&D (USD Th.), 2014-2018 Figure 184: 4D Pharma Net Loss (USD Th.) 2014-2018 Figure 185: Synlogic Inc. Investment in R&D (USD Th.), 2014-2018 Figure 186: Synlogic Inc. Net Loss (USD Th.) 2014-2018 Figure 187: Synlogic Inc. Revenue (USD Th.), 2017-2018 Figure 188: Ritter Pharmaceuticals Investment in R&D (USD Th.) 2014-2018 Figure 189: Ritter Pharmaceuticals Net Loss (USD Th.) 2014-2018 Figure 190: Assembly Bioscience Inc. Investment in R&D (USD Th.) 2014-2018 Figure 191: Assembly Bioscience Inc. Net Loss (USD Th.) 2014-2018 List Of Table Table A: Association of the Gut Microbiome with Therapeutic Effects of Drugs Table B: Prominent Human Microbiome companies operated in Americas Market Table C: Prominent Human Microbiome companies operated in Europe Market Table D: Global Access to Healthcare Index, Ranking of Select Countries in Asia Pacific Region, 2017 (score out of 10) Table E: List Of Pipeline Products Table F: Microbiome Licensing Deals Between Big Pharma & Biotech (2014-2019)

OptiBiotix Health Plc, Metabiomics, OSEL Inc., PureTech Health, 4D Pharma, Synlogic Inc., BaseClear BV, Rebiotix Inc, Ritter Pharmaceuticals, Assembly Bioscience Inc